Ripptide has been formed by the collaboration of two leading academic groups, those of Professor Jim Naismith, University of St Andrews, and Professor Marcel Jaspars, University of Aberdeen, both in Scotland.

The scientific founders have received support from a Scottish Enterprise High Growth Spin-Out grant for proof-of-concept studies and the formation of the company.

Ripptide Pharma Ltd. was founded in September 2015 to commercialise the technological breakthroughs.


Management Team

Dr Bill Primrose, CEO Technology Commercialisation (Ithaka Life Sciences Ltd.)

Dr Bill Primrose, CEO

Technology Commercialisation (Ithaka Life Sciences Ltd.)

Professor Marcel Jaspars, CSO Marine Biodiscovery Centre, Department of Chemistry (University of Aberdeen)

Professor Marcel Jaspars, CSO

Marine Biodiscovery Centre, Department of Chemistry (University of Aberdeen)

Professor Jim Naismith, CTO Director of Biomedical Sciences Research Complex (University of St Andrews)

Professor Jim Naismith, CTO

Director of Biomedical Sciences Research Complex (University of St Andrews)


Intellectual Property

  • patent application (WO2014/001822) currently in the national phase
  • second application submitted to UKPTO in November 2014